Sperandio da Silva GM, Lima LM, Fraga CAM, Sant'Anna CMR, Barreiro EJ. The molecular basis for coxib inhibition of p38alpha MAP kinase.
Bioorg Med Chem Lett 2005;
15:3506-9. [PMID:
15990304 DOI:
10.1016/j.bmcl.2005.05.107]
[Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2005] [Revised: 05/20/2005] [Accepted: 05/26/2005] [Indexed: 12/13/2022]
Abstract
In this work, we present the results of two combined approaches, molecular docking and comparative molecular field analysis (CoMFA), to propose how the selective cyclooxygenase-2 inhibitor celecoxib could act as a p38 mitogen-activated protein (MAP) kinase inhibitor. The docking analysis revealed why celecoxib has a less favorable binding energy (DeltaG= -12.4kcal/mol) than the selective p38 MAP kinase (p38 MAPK) inhibitor, SB203580 (DeltaG= -22.2kcal/mol). The CoMFA results revealed unfavorable steric effects that can be related to the predicted lower p38 MAP kinase inhibitory activity of celecoxib. Additionally, FlexX and CoMFA results also suggested that etoricoxib, another selective COX-2 inhibitor, could inhibit p38 MAP kinase.
Collapse